Skip to main content
Top
Published in: Critical Care 1/2019

Open Access 01-12-2019 | Septicemia | Letter

Matrix metalloproteinase-8: a useful biomarker to refine the diagnosis of community-acquired pneumonia upon intensive care unit admission?

Authors: Fabrice Uhel, Brendon P. Scicluna, Lonneke A. van Vught, Olaf L. Cremer, Marc J. Bonten, Marcus J. Schultz, Tom van der Poll

Published in: Critical Care | Issue 1/2019

Login to get access

Excerpt

The optimal management of severe community-acquired pneumonia (CAP) requires a prompt and accurate diagnosis [1]. Since clinical, radiological, and biological findings are poorly sensitive or specific, microbiological documentation often slow and unavailing, biomarkers could help to safely withhold antibiotics when the risk of bacterial infection is minimal and steer the diagnostic process towards non-infectious causes of respiratory failure [2]. In our previous study deriving the FAIM3:PLAC8 molecular biomarker, we noticed that MMP8, encoding matrix metalloproteinase-8 (MMP-8), was the most overexpressed gene in confirmed CAP relative to non-infectious differential diagnoses (no-CAP) [3]. We investigated in the same cohort if plasma levels of MMP-8 could be a valuable candidate biomarker for the diagnosis of CAP. …
Literature
1.
go back to reference Prina E, Ceccato A, Torres A. New aspects in the management of pneumonia. Crit Care. 2016;20:267.CrossRef Prina E, Ceccato A, Torres A. New aspects in the management of pneumonia. Crit Care. 2016;20:267.CrossRef
2.
go back to reference Christ-Crain M, Opal SM. Clinical review: the role of biomarkers in the diagnosis and management of community-acquired pneumonia. Crit Care. 2010;14:203.CrossRef Christ-Crain M, Opal SM. Clinical review: the role of biomarkers in the diagnosis and management of community-acquired pneumonia. Crit Care. 2010;14:203.CrossRef
3.
go back to reference Scicluna BP, Klein Klouwenberg PMC, van Vught LA, Wiewel MA, Ong DSY, Zwinderman AH, et al. A molecular biomarker to diagnose community-acquired pneumonia on intensive care unit admission. Am J Respir Crit Care Med. 2015;192:826–35.CrossRef Scicluna BP, Klein Klouwenberg PMC, van Vught LA, Wiewel MA, Ong DSY, Zwinderman AH, et al. A molecular biomarker to diagnose community-acquired pneumonia on intensive care unit admission. Am J Respir Crit Care Med. 2015;192:826–35.CrossRef
4.
go back to reference Schuetz P, Wirz Y, Mueller B. Procalcitonin testing to guide antibiotic therapy in acute upper and lower respiratory tract infections. JAMA. 2018;319:925–6.CrossRef Schuetz P, Wirz Y, Mueller B. Procalcitonin testing to guide antibiotic therapy in acute upper and lower respiratory tract infections. JAMA. 2018;319:925–6.CrossRef
5.
go back to reference Musher DM, Roig IL, Cazares G, Stager CE, Logan N, Safar H. Can an etiologic agent be identified in adults who are hospitalized for community-acquired pneumonia: results of a one-year study. J Infect. 2013;67:11–8.CrossRef Musher DM, Roig IL, Cazares G, Stager CE, Logan N, Safar H. Can an etiologic agent be identified in adults who are hospitalized for community-acquired pneumonia: results of a one-year study. J Infect. 2013;67:11–8.CrossRef
Metadata
Title
Matrix metalloproteinase-8: a useful biomarker to refine the diagnosis of community-acquired pneumonia upon intensive care unit admission?
Authors
Fabrice Uhel
Brendon P. Scicluna
Lonneke A. van Vught
Olaf L. Cremer
Marc J. Bonten
Marcus J. Schultz
Tom van der Poll
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Critical Care / Issue 1/2019
Electronic ISSN: 1364-8535
DOI
https://doi.org/10.1186/s13054-019-2513-7

Other articles of this Issue 1/2019

Critical Care 1/2019 Go to the issue